<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347">
  <stage>Registered</stage>
  <submitdate>31/08/2005</submitdate>
  <approvaldate>2/09/2005</approvaldate>
  <actrnumber>ACTRN12605000283673</actrnumber>
  <trial_identification>
    <studytitle>Testosterone in Obese Men Trial</studytitle>
    <scientifictitle>A 12-month Randomised, Placebo-controlled Trial of Testosterone Replacement Therapy and Lifestyle Modification Versus Lifestyle Modification Alone on Visceral Adiposity and Markers of Cardiovascular Risk in Obese Middle-Aged and Older Men</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Obese Middle-Aged and Older Men with Borderline Androgen Deficiency</healthcondition>
    <healthcondition>Testosterone deficiency in ageing males</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic and endocrine disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>12-month Randomised, Placebo-controlled Trial of Testosterone Replacement Therapy (Intramuscular Testosterone Undecanoate) and Lifestyle Modification. </interventions>
    <comparator>Lifestyle Modification Alone</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in visceral fat</outcome>
      <timepoint>After 52 weeks of intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in visceral fat</outcome>
      <timepoint>After 52 weeks of intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body Composition (Total Body Fat Mass and Fat Free Mass)</outcome>
      <timepoint>At 0 and 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Vascular Function (Pulse Wave Velocity)</outcome>
      <timepoint>At 0 and 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Metabolic (Insulin Resistance and Lipid Profiles)</outcome>
      <timepoint>At 0, 26 and 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Coagulation profiles </outcome>
      <timepoint>At 0, 6, 26, and 52 weeks.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>BMI between 30-39.9 kg/m2 and WC equal to or greater than102cm, Serum total Testosterone &lt;12nM. </inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Smokers, Significant medical condition, Sleep Apnoea, Contra-indications to Testosterone therapy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed envelopes provided by study drug manufacturer</concealment>
    <sequence>Computer generated sequence (by study drug manufacturer)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/12/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>PHIMR</primarysponsorname>
    <primarysponsoraddress>Prince Henry's Institute. Level 3, Block E, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria, 3168
Po Box 5152, Clayton, Vic, 3168</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>PHIMR</fundingname>
      <fundingaddress>Prince Henry's Institute. Level 3, Block E, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria, 3168
PO Box 5152, Clayton, Vic 3168</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Schering AG</fundingname>
      <fundingaddress>Schering Pty Ltd, 875 Pacific Highway, Pymble, NSW, 2073</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Carolyn Allan</name>
      <address>Prince Henry's Institute of Medical Research
Monash Medical Centre
Level 3 Block E
246 Clayton Road
Clayton VIC 3168</address>
      <phone>+ 61 3 95943004</phone>
      <fax>+ 61 3 95943558</fax>
      <email>carolyn.allan@princehenrys.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sr. Elise Forbes</name>
      <address>Prince Henry's Institute of Medical Research
Monash Medical Centre
Level 3 Block E
246 Clayton Road
Clayton VIC 3168</address>
      <phone>+ 61 3 95943554</phone>
      <fax>+ 61 3 95943558</fax>
      <email>elise.forbes@princehenrys.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>